Clinical Trials Logo

ADCC clinical trials

View clinical trials related to ADCC.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT03554889 Not yet recruiting - Advanced Cancer Clinical Trials

Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells

Start date: August 1, 2018
Phase: Phase 1
Study type: Interventional

NK cells can persist and expand in vivo following adoptive transfer and may have a role in the treatment of late stage malignancies. NK also express an activating Fc receptor that mediates antibody-dependent cellular cytotoxicity (ADCC) and production of immune modulatory cytokines in response to antibody-coated targets. Nimotuzumab, an monoclonal antibody against EGFR (epidermal growth factor receptor), may enhance the ADCC effect of NK cell. This study will evaluate the safety of combination of nimotuzumab and NK Cell in treating advanced cancer patients. Blood samples will also be collected for research purposes.